In agreement with an osteoclast recruitment and consequent osteolytic bone destruction, RANKL, but not OPG, expression is found at high levels in chondroblastoma specimens, and denosumab has been used neoadjuvantly for the treatment of chondroblastomas with success (Huang et al., 2003; Visgauss et al., 2021). Here, TNFSF11 is linked to chondroblastoma.